Begin main content

Brentuximab Vedotin (Adcetris) for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides - Details

Project Number pCODR 10213
Brand Name Adcetris
Generic Name Brentuximab Vedotin
Strength 50 mg
Tumour Type Lymphoma
Indication Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides
Funding Request For the treatment of adult patients with pcALCL or CD30-expressing MF who have had prior systemic therapy.
Review Status Open for Input on Submission
Pre Noc Submission No
NOC Date December 21, 2018
Manufacturer Seattle Genetics, Inc.
Sponsor Seattle Genetics, Inc.
Submission Date March 30, 2020
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ April 14, 2020
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.